publication . Article . Other literature type . 2017

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

Mattsson, Niklas; Andreasson, Ulf; Zetterberg, Henrik; Blennow, Kaj; for the Alzheimer’s Disease Neuroimaging Initiative;
Open Access English
  • Published: 27 Mar 2017
  • Country: United Kingdom
Abstract
IMPORTANCE: Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. OBJECTIVE: To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS: In this prospective case-control study, an ultrasensitive as...
Subjects
free text keywords: Original Investigation
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
Download fromView all 3 versions
UCL Discovery
Article . 2017
Europe PubMed Central
Other literature type . 2017
http://dx.doi.org/10.1001/jama...
Other literature type . 2017
Provider: Datacite
26 references, page 1 of 2

1. Mattsson N, Carrillo MC, Dean RA, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst). 2015;1(4):412-419.

2. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131- 144.

3. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67-77.

4. Nordberg A, Rinne JO, Kadir A, Långström B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6(2):78-87.

5. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015;36(5):297-309.

6. Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016;91(1):1-3. [OpenAIRE]

7. Zetterberg H, Skillbäck T, Mattsson N, et al; Alzheimer's Disease Neuroimaging Initiative. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60-67.

8. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091. [OpenAIRE]

9. Bacioglu M, Maia LF, Preische O, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91(1): 56-66.

10. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-1661.

11. Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135-140.

12. Rojas JC, Karydas A, Bang J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016;3(3):216-225. [OpenAIRE]

13. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative 14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.

15. Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336.

16. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413. [OpenAIRE]

26 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue